Top Institutional Investors

Birchview Capital, LP — 13F Holdings & Portfolio

CIK 1618205 · latest 13F-HR filed 2026-08-14

Backtest portfolio

Birchview Capital, LP manages $213.8M in 13F-reported U.S. long-equity assets across 73 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are KLAC (25.18%), BMY (8.01%), LRCX (7.09%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 14 new positions and exited 15; 30 existing positions rose in reported value and 20 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$213.8M

Long-equity book

Holdings
73

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+14 / −15 / ↑30 / ↓20

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26
KLAC25.2% · +798%BMY8.0% · -3%LRCX7.1% · -3%NTLA3.2% · -13%SLDB3.1% · +6%BDSX3.0% · 0%STOK2.7% · -15%OVV2.6% · 0%NKTR2.6% · +161%CORT2.3% · +21%NBIX2.1% · 0%PRTA2.1% · 0%ACAD2.0% · 0%PTGX2.0% · +0%CMPX1.7% · +14%RLMD1.3% · -0%ALKS1.2% · 0%HALO1.2% · +229%CLDX1.2% · -0%CYTK1.2% · 0%OLMA1.2% · -9%VERA1.2% · +31%UTHR1.1% · +0%ZBIO1.1% · +34%QURE1.1% · -50%PACB1.1% · -10%ABVX1.1% · newVIR1.0% · newBIIB0.9% · +80%EQT0.9% · 0%BIOA0.8% · newTVTX0.8% · -1%QUIDELORTHO CORP0.7% · +8%AXSM0.7% · 0%FHTX0.6% · +0%BCYC0.6% · -32%GPCR0.6% · -76%XENE0.6% · +0%NVO0.5% · newFCX0.5% · -0%IMNM0.5% · 0%PHVS0.5% · 0%HROW0.5% · 0%ADAG0.5% · newDFTX0.4% · newSLN0.4% · newBBIO0.3% · +1%FDMT0.3% · newURGN0.3% · newPHAT0.3% · -72%CAMP0.2% · newSVRA0.2% · newCADL0.2% · -20%ALT0.2% · newCMPS0.2% · -92%KPTI0.2% · -49%CGEM0.2% · 0%TRIN0.2% · 0%CAPR0.2% · newCSTL0.1% · +1%

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 59.9%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Oct 13, 2026.

Assets Under Management
$239.1M
Discretionary
$239.1M
Employees
6
Accounts
16
Address
688 PINE STREET
2ND FLOOR
BURLINGTON, VT 05401
Phone
(802) 923-3826
Website
Name Title / Status Ownership Type
BIRCHVIEW CAPITAL GP, LLC ControlGENERAL PARTNER
since Feb 2014
Less than 5%Domestic Entity
Renegar, Nicholas ControlDIRECTOR OF QUANT STRATEGIES
since Feb 2025
Less than 5%Individual
SMALL, BENJAMIN, GRANT ControlCHIEF OPERATING OFFICER
since Feb 2014
Less than 5%Individual
STROBECK, MATTHEW, WILLIAM ControlCHIEF EXECUTIVE OFFICER AND MANAGING PARTNER
since Feb 2014
75% or moreIndividual
TROTTIER, JOHN, BOARDMAN ControlCHIEF FINANCIAL OFFICER
since Nov 2022
Less than 5%Individual
TROTTIER, JOHN, BOARDMAN ControlCHIEF COMPLIANCE OFFICER
since Aug 2023
Less than 5%Individual
STROBECK, MATTHEW, WILLIAM Control
Indirect owner via BIRCHVIEW CAPITAL GP, LLC
MANAGING MEMBER
since Feb 2014
75% or moreIndividual
Ownership & leadership changes · 7 filings with changes since Apr 29, 2014

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Oct 13, 2026 filing
  • No longer listedVARMA, ERIC, KUMAR · CHIEF INVESTMENT OFFICER · Less than 5% · control person · listed since Aug 2025
Aug 21, 2025 filing
  • AddedRenegar, Nicholas · DIRECTOR OF QUANT STRATEGIES · Less than 5% · control person
  • AddedVARMA, ERIC, KUMAR · CHIEF INVESTMENT OFFICER · Less than 5% · control person
  • ChangedSTROBECK, MATTHEW, WILLIAM · title CHIEF INVESTMENT OFFICER AND MANAGING PARTNER → CHIEF EXECUTIVE OFFICER AND MANAGING PARTNER
Aug 21, 2023 filing
  • No longer listedMCCORMICK, RICHARD · CHIEF COMPLIANCE OFFICER · Less than 5% · control person · listed since Apr 2014
  • ChangedTROTTIER, JOHN, BOARDMAN · title CHIEF FINANCIAL OFFICER → CHIEF COMPLIANCE OFFICER / CHIEF FINANCIAL OFFICER
Mar 22, 2023 filing
  • AddedTROTTIER, JOHN, BOARDMAN · CHIEF FINANCIAL OFFICER · Less than 5% · control person
  • ChangedMCCORMICK, RICHARD · title CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER → CHIEF COMPLIANCE OFFICER
Mar 30, 2015 filing
  • ChangedMCCORMICK, RICHARD · now a control person
  • ChangedSTROBECK, MATTHEW, WILLIAM · title CHIEF INVESTMENT OFFICER AND LIMITED PARTNER → CHIEF INVESTMENT OFFICER AND MANAGING PARTNER
Sep 24, 2014 filing
  • ChangedMCCORMICK, RICHARD · title INTERIM CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER → CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER
May 20, 2014 filing
  • ChangedMCCORMICK, RICHARD · title INTERIM CHIEF FINANCIAL OFFICER → INTERIM CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER
  • ChangedSMALL, BENJAMIN, GRANT · title CHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER → CHIEF OPERATING OFFICER
  • ChangedSTROBECK, MATTHEW, WILLIAM · title CHIEF INVESTMENT OFFICER → CHIEF INVESTMENT OFFICER AND LIMITED PARTNER
Apr 29, 2014 filing (earliest on record)
  • ListedBIRCHVIEW CAPITAL GP, LLC · GENERAL PARTNER · Less than 5% · control person
  • ListedMCCORMICK, RICHARD · INTERIM CHIEF FINANCIAL OFFICER · Less than 5%
  • ListedSMALL, BENJAMIN, GRANT · CHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • ListedSTROBECK, MATTHEW, WILLIAM · CHIEF INVESTMENT OFFICER · 75% or more · control person
  • ListedSTROBECK, MATTHEW, WILLIAM · MANAGING MEMBER · 75% or more · indirect via BIRCHVIEW CAPITAL GP, LLC · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Birchview Capital, LP Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 KLA CORPORATION KLAC 482480100 $53.8M 25.18% 178,471 SH
2 BRISTOL-MYERS SQUIBB CO BMY 110122108 $17.1M 8.01% 297,243 SH
3 LAM RESEARCH CORPORATION LRCX 512807306 $15.2M 7.09% 35,000 SH
4 SOLID BIOSCIENCES INC SLDB 83422E204 $6.7M 3.11% 666,196 SH
5 INTELLIA THERAPEUTICS INC NTLA 45826J105 $6.5M 3.05% 385,400 SH
6 BIODESIX INC BDSX 09075X108 $6.5M 3.02% 286,804 SH
7 STOKE THERAPEUTICS INC STOK 86150R107 $5.8M 2.73% 178,110 SH
8 OVINTIV INC OVV 69047Q102 $5.7M 2.65% 107,500 SH
9 NEKTAR THERAPEUTICS NKTR 640268306 $5.7M 2.64% 81,000 SH
10 CORCEPT THERAPEUTICS INC CORT 218352102 $5.0M 2.33% 57,200 SH
11 NEUROCRINE BIOSCIENCES INC NBIX 64125C109 $4.6M 2.14% 27,190 SH
12 PROTHENA CORP PLC PRTA G72800108 $4.4M 2.06% 449,019 SH
13 ACADIA PHARMACEUTICALS INC ACAD 004225108 $4.3M 2.02% 171,000 SH
14 PROTAGONIST THERAPEUTICS INC PTGX 74366E102 $4.3M 2.01% 35,018 SH
15 COMPASS THERAPEUTICS INC CMPX 20454B104 $3.7M 1.72% 1,675,000 SH
16 RELMADA THERAPEUTICS INC RLMD 75955J402 $2.8M 1.32% 408,100 SH
17 ALKERMES PLC ALKS G01767105 $2.6M 1.23% 50,000 SH
18 HALOZYME THERAPEUTICS INC HALO 40637H109 $2.6M 1.22% 33,251 SH
19 CELLDEX THERAPEUTICS INC CLDX 15117B202 $2.6M 1.22% 69,900 SH
20 CYTOKINETICS INC CYTK 23282W605 $2.6M 1.20% 30,000 SH
21 OLEMA PHARMACEUTICALS INC OLMA 68062P106 $2.5M 1.16% 199,000 SH
22 VERA THERAPEUTICS INC VERA 92337R101 $2.5M 1.16% 57,758 SH
23 UNITED THERAPEUTICS CORP UTHR 91307C102 $2.4M 1.14% 4,506 SH
24 ZENAS BIOPHARMA INC ZBIO 98937L105 $2.4M 1.11% 93,601 SH
25 UNIQURE NV QURE N90064101 $2.3M 1.09% 50,697 SH
26 PACIFIC BIOSCIENCES OF CALIFORNIA INC PACB 69404D108 $2.3M 1.06% 1,350,000 SH
27 ABIVAX SA ABVX 00370M103 $2.3M 1.06% 17,000 SH
28 VIR BIOTECHNOLOGY INC VIR 92764N102 $2.2M 1.05% 220,000 SH
29 BIOGEN INC BIIB 09062X103 $1.9M 0.91% 9,000 SH
30 EQT CORPORATION EQT 26884L109 $1.8M 0.86% 34,619 SH
31 BIOAGE LABS INC BIOA 09077V100 $1.7M 0.79% 69,000 SH
32 TRAVERE THERAPEUTICS INC TVTX 89422G107 $1.6M 0.77% 29,000 SH
33 QUIDELORTHO CORP — 74838J101 $1.6M 0.73% 89,377 SH
34 AXSOME THERAPEUTICS INC AXSM 05464T104 $1.5M 0.69% 6,000 SH
35 FOGHORN THERAPEUTICS INC FHTX 344174107 $1.4M 0.64% 281,937 SH
36 BICYCLE THERAPEUTICS PLC BCYC 088786108 $1.3M 0.62% 313,616 SH
37 STRUCTURE THERAPEUTICS INC GPCR 86366E106 $1.3M 0.60% 24,000 SH
38 XENON PHARMACEUTICALS INC XENE 98420N105 $1.3M 0.59% 21,032 SH
39 NOVO NORDISK A/S NVO 670100205 $1.2M 0.54% 24,000 SH
40 FREEPORT-MCMORAN CL-B FCX 35671D857 $1.1M 0.53% 18,035 SH
41 IMMUNOME INC IMNM 45257U108 $1.1M 0.50% 50,000 SH
42 PHARVARIS N V PHVS N69605108 $1.0M 0.48% 29,847 SH
43 HARROW HEALTH INC HROW 415858109 $1.0M 0.48% 24,000 SH
44 ADAGENE INC ADAG 005329107 $1.0M 0.47% 240,000 SH
45 DEFINIUM THERAPEUTICS INC DFTX 24477V105 $940.8K 0.44% 20,000 SH
46 SILENCE THERAPEUTICS PLC SLN 82686Q101 $782.0K 0.37% 71,218 SH
47 BRIDGEBIO PHARMA INC BBIO 10806X102 $651.0K 0.30% 8,741 SH
48 4D MOLECULAR THERAPEUTICS INC FDMT 35104E100 $645.1K 0.30% 48,505 SH
49 UROGEN PHARMA LTD URGN M96088105 $606.7K 0.28% 16,487 SH
50 PHATHOM PHARMACEUTICALS INC PHAT 71722W107 $596.8K 0.28% 55,000 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $213.8M 73 0001618205-26-000003
2026-03-31 2026-05-15 $175.7M 73 0001618205-26-000002
2025-12-31 2026-02-13 $170.8M 68 0001618205-26-000001
2025-09-30 2025-11-13 $132.4M 69 0001618205-25-000011
Filer Information
Address
688 PINE STREET, SUITE D
C/O BIRCHVIEW CAPITAL
BURLINGTON, VT 05401
Phone
(802) 923-3826
Filing Manager
Birchview Capital, LP
BURLINGTON, VT
Signatory
Jack Trottier
CFO/CCO